Wockhardt Limited has informed the Exchange regarding a press release dated July 11, 2025, titled "Wockhardt Initiates Strategic Realignment of US Operations to Focus on Innovative Portfolio .
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Wockhardt is shutting down its loss-making US generic pharmaceutical business and will focus on its innovative drug portfolio instead. The company has filed for voluntary liquidation under Chapter 7 of the US Bankruptcy Code for two wholly-owned US subsidiaries — Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC — effective July 11, 2025. The US generics segment lost nearly USD 8 million in FY 2025. Together, these subsidiaries contributed about 3% of consolidated revenue (from Wockhardt USA LLC) and 4.6% of net worth (mostly goodwill from Morton Grove). The liquidation is expected to be completed within 15 months. Going forward, Wockhardt will double down on two areas: new antibiotic drug discovery (where it has 6 USFDA QIDP-designated programmes) and its biologicals/insulin portfolio.
In the short term, shareholders may see this negatively due to liquidation costs and the loss of revenue contribution, but the exit removes a chronic loss-making drag. Over the longer term, capital and management focus shift to higher-margin innovative and biological products, which could improve profitability if the new pipeline delivers. Net worth impact is largely limited to goodwill write-off, and India, UK, and Ireland operations remain unaffected.